CHMP positive opinion for ZS-9 in hyperkalaemia
This announcement contains inside information 24 February 2017 12:30 GMT ZS-9 (sodium zirconium cyclosilicate) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF HYPERKALAEMIA AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of ZS-9 (sodium zirconium cyclosilicate) for the treatment of hyperkalaemia, a serious condition characterised by high potassium levels in the blood serum caused by cardiovascular, renal and metabolic diseases. The